Treatment Trials

Treatment trials recruiting in the United States

(Data are as of July 24, 2009. Only select studies and criteria are given; see ClinicalTrials.gov for complete information.)

Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
Sponsored by: Eli Lilly and Company
ClinicalTrials.gov #: NCT00594568
Study Phase: Phase III

Study Location(s) and Contact Information
Nearly 50 study locations worldwide
Eli Lilly and Company
1.877.285.4559 or 1.317.615.4559

Study Purpose
This study will measure the ability of the drug LY450139 to alter the progression of Alzheimer’s disease in people with mild-to-moderate Alzheimer’s. LY450139 may inhibit the production of beta-amyloid, a protein fragment that accumulates in the Alzheimer brain and may damage cell-to-cell communication. For this effort, the researchers will use a novel brain imaging technique.

You may qualify if you

are 55 years old or older
have mild-to-moderate Alzheimer’s disease
have had both ovaries removed or have not menstruated for at least 12 consecutive months

You may not qualify if you

have depression
are not capable of swallowing whole oral medication
have a serious or unstable illness
do not have a reliable caregiver
have experienced chronic alcohol or drug abuse within the past 5 years
have ever had active vaccination for Alzheimer’s disease

Raloxifene for Women With Alzheimer's Disease
Sponsored by: National Institute on Aging; Indiana University; Kaiser Permanente; Stanford University; Southern Illinois University
ClinicalTrials.gov #: NCT00368459
Study Phase: Phase II

Study Location(s) and Contact Information
Three study locations in California, Illinois and Indiana
Narinder Bolaria, 1.650.721.3308
nbolaria@stanford.edu

Study Purpose
This study aims to determine whether the drug raloxifene improves cognitive function in women with mild-to-moderate Alzheimer's disease. Raloxifene mimics the effects of estrogen and is commonly used to treat osteoporosis, or bone thinning, in postmenopausal women.

You may qualify if you

are female and 60 years of age or older
have undergone menopause
have mild or moderate dementia or probable Alzheimer’s disease
are in otherwise good physical health
have a primary caregiver who is able to accompany you for regular assessments during the study

You may not qualify if you

have a neurological disorder besides dementia that may affect cognitive health
have diabetes or another medical condition likely to inhibit you from completing the study
have been diagnosed with major depression within the past year
have been taking experimental medication for the treatment of cognitive impairment within the past two months
have been taking estrogen, progestin or testosterone within the past two months
have been taking raloxifene within the past six months
have any allergy or intolerance to raloxifene

Anti-Psychotic Discontinuation in Alzheimer's Disease
Sponsored by: National Institute on Aging; New York State Psychiatric Institute at Columbia University
ClinicalTrials.gov #: NCT00417482
Study Phase: Phase I and Phase II

Study Location(s) and Contact Information
Seven study locations in the United States
Michelle Motta, 1.212.543.6132
mattomi@pi.cpmc.columbia.edu

Study Purpose
This study will determine the efficacy and safety of risperidone, an antipsychotic medication, in people with Alzheimer's disease that also exhibit psychotic symptoms or lack of behavioral control.

You may qualify if you

are between 45 and 90 years old
have been diagnosed with probable Alzheimer’s disease
have had intellectual impairment for at least 6 months
have an available informant who has had direct contact with you for an average of at least once every week during the three months before study entry
meet the criteria for either psychosis or behavioral dyscontrol in Alzheimer’s disease
are able to walk without the help of others
do not take psychotropic medication for at least 1 week before study entry

You may not qualify if you

have a primary psychiatric disorder predating the onset of Alzheimer’s
have a substance abuse problem within the past year
have had dementia due to head trauma
have an allergy or intolerance to risperidone
have a history of seizures, Parkinson’s disease, diffuse Lewy body disease or other neurological disorders
have untreated or incompletely treated hypothyroidism
have blindness, deafness, or any other disability that may prevent completion of the study

A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild-To-Moderate Alzheimer's Disease
Sponsored by: Pfizer; Alzheimer's Disease Cooperative Study
ClinicalTrials.gov #: NCT00566397
Study Phase: Phase II

Study Location(s) and Contact Information
More than 35 study locations in the United States
Alzheimer's Disease Education and Referral Center
1.800.438.4380 or
Pfizer CT.gov Call Center
1.800.718.1021

Study Purpose
This study is designed to evaluate the efficacy and safety of PF 04494700 in participants with mild-to-moderate Alzheimer's disease. PF 04494700 may reduce brain levels of the protein fragment beta-amyloid, a key suspect in Alzheimer’s.

You may qualify if you

are 50 years old or older
have mild-to-moderate Alzheimer’s disease

You may not qualify if you

have not been receiving Aricept® or similar drugs for at least four months before trial entry
have any non-Alzheimer brain disease or psychiatric disorder that could lead to dementia
have a family history of early-onset Alzheimer’s
have a history of type 1 or type 2 diabetes
have a history or symptoms of AIDS or other autoimmune disorders

Bapineuzumab in Patients With Mild-To-Moderate Alzheimer's Disease
Sponsored by: Elan Pharmaceuticals
ClinicalTrials.gov #: NCT00575055
Study Phase: Phase III

Study Location(s) and Contact Information
More than 125 study locations in the United States
Study coordinator, Elan Pharmaceuticals
1.866.446.5463

Study Purpose
This study will assess the effectiveness of bapineuzumab to slow the progression of Alzheimer’s disease in people with mild-to-moderate Alzheimer’s. Bapineuzumab is an antibody that binds to and clears the protein fragment beta-amyloid from the brain. Amyloid build-up is thought to disrupt cell-to-cell communication and promote brain cell death in Alzheimer’s.

You may qualify if you

are 50 to 88 years of age
have a diagnosis of probable Alzheimer’s disease
are taking stable doses of medications for Alzheimer’s
have a caregiver who can attend all clinical visits

You may not qualify if you

have a significant brain disease other than Alzheimer’s
have a major psychiatric disorder
have a history of stroke, AIDS or other major illness within the last 2 years
are smoking more than 20 cigarettes per day
have taken experimental drugs or vaccines for Alzheimer’s
are female and can still bear children
have pacemakers or other foreign metal objects in the body that prevent you from undertaking brain scans

Study Evaluating ACC-001 in Mild-To-Moderate Alzheimer's Disease Subjects
Sponsored by: Wyeth
ClinicalTrials.gov #: NCT00498602
Study Phase: Phase II

Study Location(s) and Contact Information
Thirteen study locations in the United States
Contact trial manager at clintrialparticipation@wyeth.com

Study Purpose
This study will assess the safety and efficacy of ACC-001, a compound that acts as an antibody, in people with mild-to-moderate Alzheimer's disease. ACC-001 may bind to the protein fragment beta-amyloid, a key suspect in Alzheimer’s, and help clear the fragment from the brain.

You may qualify if you

are 50 to 85 years old
have mild-to-moderate Alzheimer`s disease

You may not qualify if you

have a significant brain disease other than Alzheimer’s
have depression or another major psychiatric disorder
have a progressive illness that might hinder your ability to complete the study

A Study of V950 in People With Alzheimer's Disease
Sponsored by: Merck
ClinicalTrials.gov #: NCT00464334
Study Phase: Phase I

Study Location(s) and Contact Information
Eleven study locations in the United States, France and Sweden
Merck toll-free number, 1.800.577.8839

Study Purpose
This study will test the safety and efficacy of an investigational vaccine called V950 in people with mild-to-moderate Alzheimer’s disease. V950 is designed to lower brain levels of the protein fragment beta-amyloid, a key suspect in Alzheimer’s.

You may qualify if you

are 55 years old or older
have mild-to-moderate Alzheimer disease
have a reliable caregiver who will participate in the study

You may not qualify if you

live in a nursing home or assisted living facility
have a brain disorder other than Alzheimer’s
have had a stroke
have a history of drug or alcohol abuse
have received blood or blood derived products within 6 months of study entry

SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)
Sponsored by: National Institute on Aging
ClinicalTrials.gov #: NCT00438568
Study Phase: Phase II

Study Location(s) and Contact Information
Veterans Affairs Puget Sound Health Care System
Seattle, Washington 98108
Donna Davis, 1.206.764.2809
mollyr@u.washington.edu or
Jaime Iliff, 1.253.583.2011
Jaime.iliff@med.va.gov

Study Purpose
This study will test whether the hormone insulin, when administered as a spray into the nasal passages, improves memory in adults who have Alzheimer's disease or mild cognitive impairment, a condition that often precedes Alzheimer’s.

You may qualify if you

have been diagnosed with mild cognitive impairment or Alzheimer's disease
are in otherwise good physical health
are taking stable doses of Namenda® or other Alzheimer drugs

You may not qualify if you

have sinus problems or allergies requiring chronic use of nasal decongestants or antihistamines
have a significant brain disease other than Alzheimer’s that might affect cognitive health
have such medical illnesses as heart or kidney disease
have diabetes or are on insulin medication
have problems with liver function or have high levels of cholesterol or triglycerides
have major depression or other psychiatric disorders
have experienced chronic use of opiates, anti-psychotic medications or drugs to treat anxiety

Alzheimer's in Long-Term Care—Treatment for Agitation
Sponsored by: University of Washington; National Institute on Aging
ClinicalTrials.gov #: NCT00161473
Study Phase: Not applicable

Study Location(s) and Contact Information
Veterans Affairs Puget Sound Health Care System
Seattle, Washington 98108
Beth Hutchings, 1.800.317.5382
elizabeth.hutchings@va.gov

Study Purpose
This study will assess whether a medication called prazosin can help treat agitated and aggressive behavior in people with Alzheimer's disease and other types of dementia. Prazosin has shown success in treating post-traumatic stress disorder.

You may qualify if you

have a diagnosis of probable or possible Alzheimer’s disease

You may not qualify if you

have low blood pressure
have aggressive, uncooperative or other agitated behaviors
are using alpha-1-blockers
have schizophrenia or other psychiatric disorders
are taking medication for psychiatric disorders
have cardiovascular disease or other unstable medical condition
are currently enrolled in a separate investigational drug trial

Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease
Sponsored by: Sonexa Therapeutics, Inc.
ClinicalTrials.gov #: NCT00842673
Study Phase: Phase II

Study Location(s) and Contact Information
18 study locations in the United States and Canada
Barbra LaPlante, 1.858.356.6250

Study Purpose
This study will investigate whether the drug ST101 can safely improve memory in people with Alzheimer's disease. In earlier research with animals, the drug was shown to improve cognition and reduce Alzheimer-related protein deposits in the brain.

You may qualify if you

have evidence of mild-to-moderate Alzheimer's disease
have a reliable caregiver

You may not qualify if you

reside in a skilled nursing facility
have vitamin B12 or folate deficiency
have chronic liver disease
have a recent history of cancer
have dementia caused or complicated by a disease other than Alzheimer’s

A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-To-Moderate Alzheimer´s Disease
Sponsored by: Baxter Healthcare Corporation; Alzheimer’s Disease Cooperative Study
ClinicalTrials.gov #: NCT00818662
Study Phase: Phase III

Study Location(s) and Contact Information
33 study locations around the United States
The National Institutes of Health (NIH) Alzheimer's Disease Education and Referral Center, 1.800.438.4380 adear@nia.nih.gov

Study Purpose
The study will determine whether immune globulin intravenous injections can slow the progression of Alzheimer’s disease in people with mild-to-moderate Alzheimer’s. This drug treatment helps deliver antibodies that may help prevent the accumulation of beta-amyloid, a protein fragment that is a key suspect in Alzheimer’s.

You may qualify if you

have a diagnosis of probable Alzheimer’s disease
have taken Alzheimer medication for at least 3 months before screening
have a reliable caregiver

You may not qualify if you

have a form of dementia other than Alzheimer’s
have high blood pressure, heart disease, clotting disorders, or stroke
have bleeding in the brain detected on MRI scans
have liver or kidney disorders
have allergies to blood products
have diabetes
have had recent treatment with chemotherapy
have recently taken antibody drug therapy for Alzheimer’s disease
have had severe headaches or psychiatric problems

Safety and Efficacy Study Evaluating Dimebon in Patients with Mild-To-Moderate Alzheimer's Disease on Donepezil (CONCERT)
Sponsored by: Medivation, Inc.;
Pfizer
ClinicalTrials.gov #: NCT00829374
Study Phase: Phase III

Study Location(s) and Contact Information
44 study locations around the United States
Anthony Golsorkhi, M.D., 1.415.829.4196
anthony.golsorkhi@medivation.com
Stewart Hallett, M.B.A., 1.415.829.4113
stewart.hallett@medivation.com

Study Purpose
This study will assess the effectiveness of the drug Dimebon in people with mild-to-moderate Alzheimer's disease who are already taking donepezil (Aricept®), another Alzheimer drug. Dimebon has been shown to prevent Alzheimer-related dysfunction in mitochondria, the central energy source for all cells.

You may qualify if you

have probable Alzheimer’s disease or mild-to-moderate Alzheimer’s
have taken donepezil for at least 6 months

You may not qualify if you

have a brain disease other than Alzheimer’s
have kidney or liver disease

Effect of LY2062430 on the Progression of Alzheimer's Disease
Sponsored by: Eli Lilly and Company
ClinicalTrials.gov #: NCT00904683
Study Phase: Phase III

Study Location(s) and Contact Information
75 study locations worldwide
Eli Lilly and Company, 1.877.285.4559
1.317.615.4559

Study Purpose
This study will test whether the antibody LY2062430, or solanezumab, can slow the progression of Alzheimer’s disease in people with the disorder. Specifically, the researchers will determine whether solanezumab can 1) moderate buildup of the protein fragment beta-amyloid, a key suspect in Alzheimer’s, and 2) slow cognitive and functional decline in their participants. Solanezumab works as a monoclonal antibody—that is, it binds to beta-amyloid and helps remove it from the body. In addition, the compound has been designed so that it should not cause brain inflammation, a problem that characterized earlier beta-amyloid antibodies.

You may qualify if you

have mild-to-moderate Alzheimer’s disease
have been on Alzheimer medication for at least 4 months before study entry
have a reliable caregiver

You may not qualify if you

have vascular dementia
have experienced head trauma or had an infectious brain disease in the last
five years
are allergic to the antibodies in the study
have had chronic alcohol or drug abuse in the past 5 years
are unable to safely undergo MRI scans
have a disorder that requires treatment with a monoclonal antibody other than solanezumab
have any other unstable medical condition

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (TEAM-AD)
Sponsored by: Department of Veterans Affairs; Forest Laboratories; DSM Nutritional Products, Inc.
ClinicalTrials.gov #: NCT00235716
Study Phase: Phase III

Study Location(s) and Contact Information
13 study locations in the United States and Puerto Rico
Susan Love, M.A., 1.612.467.3342
lovex008@tc.umn.edu
Julie Tomaska, M.S.P.H., 1.612.467.1563
julie.tomaska@va.gov

Study Purpose
This study will assess the benefits of using a combination of vitamin E and the drug memantine to treat people with mild-to-moderate Alzheimer’s disease. Memantine has been shown to improve the ability of brain cells to communicate with one another. Vitamin E is known to reduce the harmful effects of Alzheimer-related oxidative stress, or damage to brain cells caused by toxic oxygen molecules.

You may qualify if you

have a diagnosis of probable or possible Alzheimer’s disease
have been on a regular dosage of donepezil (Aricept®), rivastigmine (Exelon®), or galantamine (Razadyne®) for a minimum of 4 weeks
have a reliable caregiver
agree not to take vitamin E supplements or memantine outside of the study

You may not qualify if you

have a form of dementia not related to Alzheimer’s
reside in a skilled nursing or assisted living facility
have an alcohol or drug addiction
have psychiatric disorders, including depression or schizophrenia
are enrolled in another clinical drug trial
take warfarin
take amantadine or vitamin E supplements in the 2 weeks before study enrollment
have used memantine in the past 4 weeks

Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm2 Patch in Patients With Alzheimer's Disease Showing Cognitive Decline
Sponsored by: Novartis
ClinicalTrials.gov #: NCT00506415
Study Phase: Phase III

Study Location(s) and Contact Information
152 study locations worldwide
Novartis, 1.862.778.8300

Study Purpose
This study will test whether the drug rivastigmine, if administered through a skin patch, can safely improve cognitive function in people with Alzheimer’s disease. Rivastigmine is designed to increase brain levels of acetylcholine, a chemical messenger involved in memory and other thought processes.

You may qualify if you

are between 50 and 85 years old
have a diagnosis of probable Alzheimer’s disease
have a reliable primary caregiver

You may not qualify if you

have a form of dementia unrelated to Alzheimer’s
have depression or other psychiatric disorder
have cerebrovascular disease or cardiovascular disease
have any other medical condition that would interfere with study participation

A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild-To-Moderate Alzheimer's Disease
Sponsored by: Bristol-Myers Squibb
ClinicalTrials.gov #: NCT00810147
Study Phase: Phase II

Study Location(s) and Contact Information
41 study locations around the United States, Denmark, Finland, and Sweden
Bristol-Myers Squibb contact, Clinical.Trials@bms.com
U.S. government website, clinicaltrials.gov/ct2/show/study/NCT00810147

Study Purpose
This study will assess whether the drug BMS-708163 can safely reduce levels of the protein fragment beta-amyloid, a key suspect in Alzheimer’s disease, in patients with mild-to-moderate Alzheimer's. BMS-708163 has been shown to disrupt the production of beta-amyloid from its “parent” molecule.

You may qualify if you

have a diagnosis of mild-to-moderate Alzheimer’s disease
have undergone cognitive decline for 6 months
have taken Alzheimer medication for 2 months
have a reliable caregiver

You may not qualify if you

have a form of dementia other than Alzheimer’s
have a history of stroke
have a compromised immune system
have peptic ulcers, chronic inflammatory bowel disease, or chronic diarrhea
have unstable vitamin B-12 deficiency
have alcohol or drug addiction
have significant drug allergies
have been involved in another experimental drug study
are a woman of childbearing potential
have a psychiatric illness
reside in a nursing home or skilled nursing facility
are unable to swallow capsules

Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease
Sponsored by: Epix Pharmaceuticals, Inc.
ClinicalTrials.gov #: NCT00693004
Study Phase: Phase II

Study Location(s) and Contact Information
33 study locations in the United States
Julia Kazakin, M.D., 1.781.761.7646
jkazakin@epixpharma.com

Study Purpose
This study will assess the ability of the drug PRX-03140 to improve cognitive function in people with Alzheimer's disease. PRX-03140 has been shown to improve cell-to-cell communication in the brain.

You may qualify if you

have a diagnosis of probable Alzheimer’s disease
are between 50 and 90 years of age
have a regular caregiver

You may not qualify if you

have a diagnosis of vascular dementia
have heart abnormalities
have a history of uncontrolled seizure disorder within 12 months of trial entry
have a history of schizophrenia or other significant psychiatric illness
have vitamin B12 deficiency, syphilis, a positive HIV test or abnormal thyroid function
have a history of drug or alcohol abuse
have taken an investigational drug within 30 days of trial entry
have been on cholinesterase inhibitors for more than 2 years, or less than 2 months before trial entry
have an intolerance or allergy to cholinesterase inhibitors

A Study of PRX-03140 in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil
Sponsored by: Epix Pharmaceuticals, Inc.
ClinicalTrials.gov #: NCT00672945
Study Phase: Phase II

Study Location(s) and Contact Information
37 study locations in the United States
Julia Kazakin, M.D., 1.781.761.7646
jkazakin@epixpharma.com

Study Purpose
This study will test whether the drug PRX-03140 can improve cognitive function in people with Alzheimer's disease. PRX-03140 has been shown to improve cell-to-cell communication in the brain. Participants in this study will also be taking donepezil (Aricept®), another drug designed to improve cognitive function.

You may qualify if you

are between 50 and 90 years of age
have a diagnosis of probable Alzheimer’s disease
have received a stable dose of donepezil (Aricept®) for at least 4 months
have a regular caregiver who is willing to attend all study visits

You may not qualify if you

have vascular dementia
have heart problems
have a history of uncontrolled seizure disorder within 12 months of enrollment
have a history of psychiatric illness such as schizophrenia
have vitamin B12 deficiency, syphilis, a positive HIV test, or abnormal thyroid function
have had cognitive rehabilitation within 6 months of study entry
have a history of drug or alcohol abuse
received memantine within 2 months of enrollment
have taken prescription cholinesterase inhibitors for Alzheimer’s, other than donepezil, within 4 months of enrollment
have taken an investigational drug within 30 days of test entry

Efficacy and Safety of T-817MA in Patients With Mild-To-Moderate Alzheimer's Disease
Sponsored by: Toyama Chemical Co., Ltd.
ClinicalTrials.gov #: NCT00663936
Study Phase: Phase II

Study Location(s) and Contact Information
24 study locations around the United States
Jeremy Johnston, 1.800.554.0502, ext. 294
Jeremy.Johnston@mdsinc.com

Study Purpose
This study will evaluate whether the drug T-817MA can safely moderate the development of Alzheimer’s disease. T-817MA works by protecting neurons from oxidative stress, or damage to brain cells caused by toxic oxygen molecules. Oxidative stress is an important feature of Alzheimer’s.

You may qualify if you

have mild-to-moderate Alzheimer's disease and are receiving donepezil (Aricept®)
are 50 to 90 years old
have an eligible caregiver or informant

You may not qualify if you

have heart, liver, or kidney impairment
have a dementia that is not Alzheimer's
are taking any drug other than donepezil for Alzheimer's disease—including rivastigmine, galantamine, memantine, or tacrine—within 12 weeks of study entry

A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease
Sponsored by: Genentech
ClinicalTrials.gov #: NCT00736775
Study Phase: Phase I

Study Location(s) and Contact Information
Eight study locations around the United States
Molly Mollough
robison.molly@gene.com
Genentech clinical trial support line, 1.888.662.6728

Study Purpose
This study will test whether the drug MABT5102A can reduce levels of the protein fragment beta-amyloid, a key suspect in Alzheimer’s disease, in people with mild-to-moderate Alzheimer's. MABT5102A is an antibody that can bind to beta-amyloid and target it for removal by the body’s immune system.

You may qualify if you

have a diagnosis of probable Alzheimer’s disease
have been taking stable doses of cholinesterase inhibitors or other Alzheimer medications for 3 months or less before screening
have been taking stable doses of other prescription medications for one month or less before screening

You may not qualify if you

have had any non-Alzheimer disease of the central nervous system
have a history of treatment with any drug that targets beta-amyloid

Safety and Tolerability of Repeated Subcutaneous Injections of CAD 106 in Mild Alzheimer's Patients
Sponsored by: Novartis
ClinicalTrials.gov #: NCT00795418
Study Phase: Phase II

Study Location(s) and Contact Information
10 study locations around the United States
Novartis Pharmaceuticals, 1.862.778.8300

Study Purpose
This study will evaluate whether the drug CAD 106 can reduce levels of beta-amyloid in people with mild Alzheimer’s disease. Beta-amyloid is a protein fragment that is a key suspect in Alzheimer’s. CAD 106 is designed to produce antibodies that can bind to beta amyloid and help remove it from the brain. The researchers will administer the drug by injection under the skin.

You may qualify if you

have a diagnosis of mild Alzheimer’s disease
are between 40 and 85 years of age

You may not qualify if you

have been on Alzheimer medication, such as cholinesterase inhibitors, for more than 6 weeks before study entry
have participated in an earlier Alzheimer vaccine study and received active treatment
have had a condition involving chronic inflammation
have had AIDS or another autoimmune disorder
have a history of seizures or cerebrovascular disease
have had a non-Alzheimer brain disease
have a psychiatric disorder; however people with depression that is under treatment will be considered
have another disease that might interfere with your safety during the study

Treatment for Aggression and Agitation in Patients With Alzheimer's Disease
Sponsored by: Eli Lilly and Company
ClinicalTrials.gov #: NCT00843518
Study Phase: Phase II

Study Location(s) and Contact Information
14 study locations around the United States
Study director, 1.877.285.4559 or 1.317.615.6559

Study Purpose
This study hopes to determine whether the drug LY451395 can ameliorate symptoms of aggression and agitation in people with Alzheimer's disease. LY451395 helps regulate the processing of glutamate, a chemical messenger in the brain that plays an important role in cell-to-cell communication.

You may qualify if you

have a diagnosis of probable Alzheimer’s disease
are at least 60 years of age
have a weight of about 100 pounds (45 kilograms) or more
show persistent behavior involving verbal or physical agitation and verbal or physical aggression that may disrupt your ability to function normally

You may not qualify if you

have delirium
have vascular dementia
have brain disorders other than Alzheimer’s disease
take an acetylcholinesterase inhibitor or memantine for less than 4 months before study entry

A Phase 3 Study to Evaluate the Safety And Tolerability Of Dimebon Patients With Mild-To-Moderate Alzheimer's Disease
Sponsored by: Pfizer; Medivation, Inc.
ClinicalTrials.gov #: NCT00838110
Study Phase: Phase III

Study Location(s) and Contact Information
111 study locations around the United States, Canada, and Puerto Rico
Pfizer CT.gov Call Center, 1.800.718.1021

Study Purpose
This study will assess the ability of the drug Dimebon to improve cognition and daily functioning in people with mild-to-moderate Alzheimer’s disease. Dimebon may prevent Alzheimer-related abnormalities in structures called mitochondria, the central sources of energy for all cells. Such abnormalities often lead to the death of neurons.

You may qualify if you

have a diagnosis of Alzheimer’s disease
have been on anti-dementia drug therapy treatment, including cholinesterase inhibitors or memantine, for at least 60 days before study entry

You may not qualify if you

have a major structural brain disease other than Alzheimer’s
have any major medical illness that may interfere with your ability to comply with study procedures and abide by study restrictions
reside in a nursing home or assisted living facility, with need for 24-hour care and supervision

A Study of SB-742457, Added to Donepezil, for the Treatment of Mild-To-Moderate Alzheimer's Disease
Sponsored by: GlaxoSmithKline
ClinicalTrials.gov #: NCT00710684
Study Phase: Phase II

Study Location(s) and Contact Information
97 study locations worldwide
U.S. GlaxoSmithKline Clinical Trials Call Center,
1.877.379.3718

Study Purpose
This study will investigate whether the drug SB-742457 can improve cognitive function in people with mild-to-moderate Alzheimer's disease. SB-742457 is designed to improve the function of chemical messengers called neurotransmitters in the brain.

You may qualify if you

have a diagnosis of probable mild-to-moderate Alzheimer’s disease
have been taking a stable dose of donepezil (Aricept®) for at least 2 months before study entry
have a regular caregiver
are a woman of childbearing potential and agree to abstinence or an approved form of birth control

You may not qualify if you

have unacceptable blood pressure readings
have possible, probable, or definite vascular dementia
have hypersensitivity to sunlight or a history of seizures
have previous exposure to SB-742457 or are taking medication that might negatively interact with the study medication

Efficacy and Safety of Plasma Exchange With 5 Percent Albutein in Beta-Amyloid Peptide Clearance in Cerebrospinal Fluid
Sponsored by: Grifols Biologicals Inc.
ClinicalTrials.gov #: NCT00742417
Study Phase: Phase II

Study Location(s) and Contact Information
Two study locations in New Jersey and the District of Columbia
Paul Pinciaro, Director of Clinical Development,
1.443.375.8825
Paul.Pinciaro@grifols.com
Marinda Beach, Project Manager, 1.540.428.2828
marindabeach@crofessionals.com

Study Purpose
This study will evaluate a procedure for reducing levels of the protein fragment beta-amyloid, a key suspect in Alzheimer’s disease, in people with mild-to-moderate Alzheimer’s. The procedure involves administering blood plasma that can lower beta-amyloid levels in the cerebrospinal fluid surrounding the brain. Such efforts could help reduce beta-amyloid clumping in the brain.

You may qualify if you

have a diagnosis of Alzheimer’s disease
have been on a stable treatment of cholinesterase inhibitors for three months
have a reliable caretaker that will attend study visits

You may not qualify if you

have uncontrolled high blood pressure
have cerebrovascular disease
have liver problems or heart disease
have blood clotting disorders
have psychiatric or behavioral problems
have insomnia
have a history of adverse reactions to blood products
have participated in other clinical trials or taken any investigational drug in the three months before study entry

A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild-To-Moderate Alzheimer's Disease
Sponsored by: Hoffmann-La Roche
ClinicalTrials.gov #: NCT00884507
Study Phase: Phase II

Study Location(s) and Contact Information
62 study locations worldwide
Study director, 1.973.235.5000 or
1.800.526.6367 (for U.S. locations only)
When calling, please reference study ID #: WN22018

Study Purpose
This study will assess the ability of the drug RO5313534 to improve cell-to-cell communication in the brains of people with mild-to-moderate Alzheimer's disease. RO5313534 is designed to promote the activity of chemical messengers in the brain called neurotransmitters. The participants in this study will also take the Alzheimer drug donepezil (Aricept®).

You may qualify if you

have a diagnosis of probable Alzheimer’s disease
are 50 to 85 years of age
are under donepezil treatment 4 months or less before study entry
do not require nursing home care, but are looked after by a caregiver

You may not qualify if you

have dementia due to a condition other than Alzheimer's disease
have another significant neurological disorder
have an untreated or unstable psychiatric condition, including depressive disorder, bipolar disorder, and schizophrenia

Study Comparing Three Dosage Levels of SAM-531 in Outpatients With Mild-To-Moderate Alzheimer Disease
Sponsored by: Wyeth
ClinicalTrials.gov #: NCT00895895
Study Phase: Phase II

Study Location(s) and Contact Information
31 study locations in the United States and Japan
Trial Manager, clintrialparticipation@wyeth.com

Study Purpose
This study will evaluate whether the drug SAM-531 can improve cell-to-cell communication in the Alzheimer brain. SAM-531 is designed to promote the activities of chemical messengers, or neurotransmitters, in the brain.

You may qualify if you

have a diagnosis of probable Alzheimer’s disease

You may not qualify if you

have a brain disease other than Alzheimer’s that may affect cognition
have aggressive, uncooperative, or other agitated behaviors
have a history of stroke

Alzheimer's Disease: Potential Benefit of Isoflavones
Sponsored by: University of Wisconsin, Madison;
National Institutes of Health (NIH)
ClinicalTrials.gov #: NCT00205179
Study Phase: Phase II

Study Location(s) and Contact Information
University of Wisconsin
Madison, Wisconsin, 53792
Kirsten Walth, 1.866.636.7764
memory-research@medicine.wisc.edu

Study Purpose
This pilot study will evaluate the effects of soy isoflavone supplements on cognitive function in people with Alzheimer's Disease. Preliminary studies have suggested that soy supplements may ameliorate cognitive decline in older adults diagnosed with Alzheimer's compared with volunteers taking a placebo.

You may qualify if you

have a diagnosis of probable Alzheimer’s disease
are on a stable dose of cholinesterase inhibitors
have a reliable caregiver

You may not qualify if you

have a history or significant gastrointestinal or colon disease
have irritable bowel syndrome
have a history of breast cancer or abnormal mammogram within 12 months before study screening
have a history of chronic obstructive pulmonary disease, diabetes mellitus, liver disease, or unstable ischemic heart disease
have a significant neurological disease other than Alzheimer’s that might affect cognitive function—including stroke, Parkinson's disease, multiple sclerosis, or serious traumatic brain injury
have used menopausal hormone replacement therapy within the 6 months before trial screening
have used oral antibiotic therapy within 4 months before trial screening
take 5 milligrams per day or more of soy isoflavones

Study Evaluating Bapineuzumab in Alzheimer Disease Subjects
Sponsored by: Wyeth
ClinicalTrials.gov #: NCT00663026
Study Phase: Phase II

Study Location(s) and Contact Information
18 study locations around the United States
Trial Manager, clintrialparticipation@wyeth.com

You may qualify if you

have a diagnosis of probable Alzheimer’s disease

You may not qualify if you

have non-Alzheimer brain abnormalities
have schizophrenia or another psychiatric disorder

Hormone and Information Processing Study (HIP)
Sponsored by: National Institute on Aging (NIA); Solvay Pharmaceuticals
ClinicalTrials.gov #: NCT00539305
Study Phase: Phase III

Study Location(s) and Contact Information
Veterans Affairs Puget Sound Health Care Systems
Seattle, Washington 98108
Christina Bradic, 1.206.277.1155
cb80@u.washington.edu
Gareth Holman, 1.206.277.5055
gholman@u.washington.edu

Study Purpose
This study will examine whether testosterone therapy can improve cognitive function in older men with low testosterone levels and mild cognitive impairment, a condition that often precedes Alzheimer’s disease. The researchers will also assess whether testosterone can moderate harmful protein buildup in the brain and other biological hallmarks of Alzheimer’s.

You may qualify if you

have a diagnosis of mild cognitive impairment
are male and from 60 to 90 years of age
have low testosterone levels
have a capable informant
have normal blood chemistry
have a body mass index of less than 33 kg/m2 and a stable weight in the year before study entry
have been on a stable dose of cholinesterase inhibitors or anti-depressants for three months or more

You may not qualify if you

have a history of prostate cancer or other prostate disorders
have vascular disease
have a history of severe head injury
have neurological illness such as Parkinson's disease, seizure disorder, multiple sclerosis, or major stoke
have psychiatric illness, including schizophrenia or bipolar disorder
have a history of alcohol or drug abuse
smoke cigarettes
are taking anti-convulsants, anti-psychotics, sedating antihistamines, sedatives, hormone or testosterone treatments or flutamide